-- Phexxi is the first and only hormone-free
contraceptive offered by reproductive telehealth leader
SimpleHealth to its patients --
SAN
DIEGO, Feb. 28, 2023 /PRNewswire/ -- Evofem
Biosciences, Inc. (OTCQB: EVFM) announced today that reproductive
telehealth leader SimpleHealth now offers Phexxi® (lactic
acid, citric acid and potassium bitartrate), the first and only
hormone-free vaginal gel approved by the FDA for contraception.
"This partnership with SimpleHealth will increase awareness of
Phexxi and provide access to the only non-hormonal birth control
women use on demand," said Saundra
Pelletier, Chief Executive Officer of Evofem. "This
beneficial alliance "meets" women where they are and delivers on
our strategy to expand access to Phexxi."
"SimpleHealth believes everyone deserves access to birth
control. We are proud to offer Phexxi to meet the needs of the many
women who want or need a non-hormonal birth control method," said
Carrie Siu Butt, Chief Executive
Officer of SimpleHealth.
The SimpleHealth offering includes contraceptive counseling,
resources, and education about women's health as well as online
prescriptions, automatic refills and free home delivery of more
than 120 brand name and generic products including hormonal birth
control – pill, patch or ring – and now hormone-free Phexxi
contraceptive vaginal gel.
Phexxi appeals to a wide variety of women who seek hormone-free
contraception, whether by need or by choice, offering them a safe
and effective, FDA-approved contraceptive method that empowers
women with access to contraception they use only when they need
it.
About SimpleHealth
Launched in 2016,
SimpleHealth is a leading digital healthcare platform that
makes access to reproductive wellness convenient and easy for its
patients. The Company is focused on providing access and
expert care to allow women to realize their potential through a
healthy reproductive system.
About Evofem
Evofem Biosciences, Inc., is
developing and commercializing innovative products to address unmet
needs in women's sexual and reproductive health. The Company's
first FDA-approved product, Phexxi® (lactic
acid, citric acid and potassium bitartrate), is
a hormone-free, on-demand prescription contraceptive vaginal
gel. It comes in a box of 12 pre-filled applicators and is applied
0-60 minutes before each act of sex. Learn more
at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem
Biosciences, Inc.
Forward-Looking Statements
This press release
includes "forward-looking statements," within the meaning of the
safe harbor for forward-looking statements provided by Section 21E
of the Securities Exchange Act of 1934, as amended, and the Private
Securities Litigation Reform Act of 1995 including, without
limitation, statements related to the expected impact of
the partnership to increase awareness of and access to
Phexxi. You are cautioned not to place undue reliance on
these forward-looking statements, which are current only as of the
date of this press release. Each of these forward-looking
statements involves risks and uncertainties. Important factors that
could cause actual results to differ materially from those
discussed or implied in the forward-looking statements are
disclosed in the Company's SEC filings, including its Annual Report
on Form 10-K for the year ended December 31, 2021, filed with
the SEC on March 10, 2022, its Quarterly Report on Form 10-Q
for the quarter ended September 30, 2022 filed with the
SEC on January 6, 2023 and any subsequent filings. All
forward-looking statements are expressly qualified in their
entirety by such factors. The Company does not undertake any duty
to update any forward-looking statement except as required by
law.
Contacts
Evofem Biosciences,
Inc.
Amy Raskopf
SVP, Investor Relations
araskopf@evofem.com /
media@evofem.com
(917) 673-5775
Simple Health
press@simplehealth.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evofems-phexxi-contraceptive-gel-added-to-simplehealth-product-offering-301757646.html
SOURCE Evofem Biosciences, Inc.
